Curis Files Prospectus Supplement for Stock Offering

Curis ( (CRIS) ) has provided an update.

On August 8, 2025, Curis, Inc. announced the filing of a prospectus supplement under its universal shelf registration statement with the SEC, allowing for the offer and sale of up to $8,137,047 of common stock. This move follows the company’s decision on July 1, 2025, to terminate a prior prospectus related to a larger offering, while maintaining the existing sales agreement with Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC. The legal opinion regarding the shares was provided by Wilmer Cutler Pickering Hale and Dorr LLP.

The most recent analyst rating on (CRIS) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.

Spark’s Take on CRIS Stock

According to Spark, TipRanks’ AI Analyst, CRIS is a Neutral.

Curis’ overall score is driven by significant clinical trial progress, which suggests potential future growth, despite current financial instability and valuation concerns. The positive earnings call sentiment regarding clinical developments was a key factor, though offset by substantial financial risks and weak technical indicators.

To see Spark’s full report on CRIS stock, click here.

More about Curis

Curis, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapeutics for the treatment of cancer.

Average Trading Volume: 113,669

Technical Sentiment Signal: Sell

Current Market Cap: $20.87M

Learn more about CRIS stock on TipRanks’ Stock Analysis page.